P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site
Background. Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between pri...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2017/4537532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224213233762304 |
|---|---|
| author | Jonathan D. Marotti Kristen E. Muller Laura J. Tafe Eugene Demidenko Todd W. Miller |
| author_facet | Jonathan D. Marotti Kristen E. Muller Laura J. Tafe Eugene Demidenko Todd W. Miller |
| author_sort | Jonathan D. Marotti |
| collection | DOAJ |
| description | Background. Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between primary and metastatic human breast tumors and between breast cancer subtypes. Design. P-Rex1 expression was measured in 133 specimens by immunohistochemistry: 40 and 42 primary breast tumors from patients who did versus did not develop metastasis, respectively, and 51 breast-derived tumors from metastatic sites (36 of which had matching primary tumors available for analysis). Results. Primary breast tumors showed significant differences in P-Rex1 expression based on receptor subtype. ER+ and HER2+ primary tumors showed higher P-Rex1 expression than primary triple-negative tumors. HER2+ metastases from all sites showed significantly higher P-Rex1 expression compared to other metastatic receptor subtypes. Solid organ (i.e., brain, lung, and liver) metastases showed higher P-Rex1 expression compared to bone metastases. Conclusions. P-Rex1 expression is increased in ER+ and HER2+ breast cancers compared to triple-negative tumors. P-Rex1 may be differentially expressed in metastatic tumors based on site and receptor status. The role of P-Rex1 in the development of breast cancer metastases and as a predictive biomarker of therapeutic response warrants further investigation. |
| format | Article |
| id | doaj-art-5257efab128c4d16aff4b241fa1b45e2 |
| institution | OA Journals |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-5257efab128c4d16aff4b241fa1b45e22025-08-20T02:05:42ZengWileyInternational Journal of Breast Cancer2090-31702090-31892017-01-01201710.1155/2017/45375324537532P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic SiteJonathan D. Marotti0Kristen E. Muller1Laura J. Tafe2Eugene Demidenko3Todd W. Miller4Department of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USADepartment of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USADepartment of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USADepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, USAComprehensive Breast Program, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USABackground. Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between primary and metastatic human breast tumors and between breast cancer subtypes. Design. P-Rex1 expression was measured in 133 specimens by immunohistochemistry: 40 and 42 primary breast tumors from patients who did versus did not develop metastasis, respectively, and 51 breast-derived tumors from metastatic sites (36 of which had matching primary tumors available for analysis). Results. Primary breast tumors showed significant differences in P-Rex1 expression based on receptor subtype. ER+ and HER2+ primary tumors showed higher P-Rex1 expression than primary triple-negative tumors. HER2+ metastases from all sites showed significantly higher P-Rex1 expression compared to other metastatic receptor subtypes. Solid organ (i.e., brain, lung, and liver) metastases showed higher P-Rex1 expression compared to bone metastases. Conclusions. P-Rex1 expression is increased in ER+ and HER2+ breast cancers compared to triple-negative tumors. P-Rex1 may be differentially expressed in metastatic tumors based on site and receptor status. The role of P-Rex1 in the development of breast cancer metastases and as a predictive biomarker of therapeutic response warrants further investigation.http://dx.doi.org/10.1155/2017/4537532 |
| spellingShingle | Jonathan D. Marotti Kristen E. Muller Laura J. Tafe Eugene Demidenko Todd W. Miller P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site International Journal of Breast Cancer |
| title | P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site |
| title_full | P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site |
| title_fullStr | P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site |
| title_full_unstemmed | P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site |
| title_short | P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site |
| title_sort | p rex1 expression in invasive breast cancer in relation to receptor status and distant metastatic site |
| url | http://dx.doi.org/10.1155/2017/4537532 |
| work_keys_str_mv | AT jonathandmarotti prex1expressionininvasivebreastcancerinrelationtoreceptorstatusanddistantmetastaticsite AT kristenemuller prex1expressionininvasivebreastcancerinrelationtoreceptorstatusanddistantmetastaticsite AT laurajtafe prex1expressionininvasivebreastcancerinrelationtoreceptorstatusanddistantmetastaticsite AT eugenedemidenko prex1expressionininvasivebreastcancerinrelationtoreceptorstatusanddistantmetastaticsite AT toddwmiller prex1expressionininvasivebreastcancerinrelationtoreceptorstatusanddistantmetastaticsite |